Interviewing the CEO who uses Probiotics as Needle-free Vaccines

27/04/2016 - 1 minute

This is my first interview from BioTrinity 2016 in London. I met with Tom Johnston, CEO of Mucosis, to learn more about the needle-free vaccine platform he is developing.


Mucosis is a biotechnology company based in Gröningen, Netherlands (a city we covered here for its medtech innovation). It was founded in 2007 and has raised over €20M so far.

The company is using safe probiotics as antigen presenters to develop an innovative mucosal vaccines which can be administered needle-free via the nose or mouth.

The lead product is preparing for a Phase I trial in September, with hopes to potentially start Phase II next year. Notably, the company got a €3.7M funding from the Wellcome Trust earlier this year, which is a great recognition of the potential of the platform.

So I asked Tom my more pressing questions to better understand their technology…Please accept preferences cookies to watch this video.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member